stella
beta
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms — Stella
Recruiting
Back to Recurrent Chronic Myelomonocytic Leukemia trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Mayo Clinic in Rochester, Rochester, Minnesota
View full record on ClinicalTrials.gov